Atenolol Market Trends

  • Report ID: 4076
  • Published Date: Jul 25, 2024
  • Report Format: PDF, PPT

Atenolol Market Trends

Growth Drivers

  • Growing Prevalence of Angina Experiences - Angina is a type of chest pain that occurs by a decrease in blood flow to the heart. It is mainly caused by an accumulation of fatty deposits in the arteries supplying blood to the heart muscles. In such a condition, the heart beats faster and a person feels a sharp pain and pressure in his/her chest. It is an early sign of heart disorders. Atenolol belongs to a class of drugs referred to as beta blockers. Beta-blockers decrease the oxygen demand of the heart and lower the occurrence of angina attacks by reducing heart rate. Hence, the increasing prevalence of angina attacks is estimated to expand market growth further over the projected time frame. For instance, in the United States, each year angina affects more than 9 million people.
  • Expansion in Sedentary Lifestyle - Physical inactivity can have major adverse health effects. An inactive lifestyle raises the risk of all causes that result in death and doubles the chance of a variety of conditions such as cardiovascular disease, diabetes, obesity, anxiety, and so on. Therefore, an increase in sedentary lifestyles is also projected to drive the growth of the atenolol market in the coming years. As reported by the World Health Organization, 27% of adults and more than 80% of adolescents globally fail to comply with the recommended physical activity ratio.
  • Increasing Prevalence of Arrhythmia - Any issue with a person's heartbeat rate or rhythm is referred to as an "arrhythmia." Electrical waves that are too fast, too slow, or chaotic during an arrhythmia can cause an irregular heartbeat. The heart cannot properly pump blood when it is not beating appropriately. The lungs, brain, and all the other organs are unable to function properly and may get damaged. Atenolol helps in this situation by lowering your heart rate, which makes it easier for your heart to circulate blood throughout the organs. Thus, the rising prevalence of arrhythmia is also estimated to boost the market growth of atenolol over the forecast period. As per an estimation, Arrhythmia is anticipated to affect approximately 1.7% to 6% of the overall population in the United States.
  • Rise in Poor Dietary Habits - According to a new worldwide study conducted in 2021, approximately 50% of the global population suffers from poor dietary habits, which has negative consequences for people.
  • Rising Cases of Cardiovascular Disorders – Based on the World Health Organization figures, cardiovascular diseases are the most prevalent cause of death throughout the world, claiming the lives of an estimated 17.9 million people annually.

Challenges

  • Associated Side Effects of Atenolol – Though atenolol helps to tackle several kinds of hypertension issues still numerous side effects are associated with the use of atenolol comprising feeling sleepiness, dizziness, nausea, hypotension, blurred vision, bloody urination, and so on. Hence, this factor is anticipated to dampen the growth of the market in the coming years.
  • Availability of Diuretics and Other Drugs
  • Risk of Interaction with Other Drugs

Atenolol Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

5.4%

Base Year Market Size (2023)

USD 11.59 Billion

Forecast Year Market Size (2036)

USD 22.97 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4076
  • Published Date: Jul 25, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of atenolol is assessed at USD 12.15 Billion.

The atenolol market size was valued at USD 11.59 Billion in 2023 and is expected to reach USD 22.97 Billion by the end of 2036, expanding at around 5.4% CAGR during the forecast period i.e., between 2024-2036. Growing prevalence of angina experiences, expansion in sedentary lifestyle, and increasing prevalence of arrhythmia are the major factors driving the market growth.

North America is likely to be the largest with a share of about 40% by 2036, attributed to increasing prevalence of cardiac diseases, along with rising frequency of hypertension in the region.

Intas Pharmaceuticals Limited, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals (USA) Inc., Ipca Laboratories Limited, Unichem Laboratories Limited, AstraZeneca PLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample